JUPITER NEUROSCIENCES INC
JUNSNASDAQTrading Snapshot
- Day Range
- $2.40 – $2.70
- 52-Week Range
- $2.25 – $127.50
- Volume (shares)
- 29,722
- Avg Volume (shares)
- —
- Shares Outstanding
- 1.3M
- Next Earnings
- 2026-12-02
Fundamentals Snapshot
- Annual Revenue
- $21,796
- Last Q Revenue
- $24,245
- P/E Ratio
- -0.1
- P/S Ratio
- 51.0x
- EPS (TTM)
- $-16.50
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +19.7%
JUPITER NEUROSCIENCES INC
JUNS
StockOtter · stockotter.spaceAbout JUPITER NEUROSCIENCES INC
Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues. Also in Phase II, JNS102 is being developed for mucopolysaccharidosis Type I, JNS107 for MELAS Syndrome, and JNS108 for mild cognitive impairment and early Alzheimer's disease. Furthermore, the company is progressing JNS109 for amyotrophic lateral sclerosis, JNS110 for traumatic brain injury and concussion, and JNS120 as a treatment for COVID-19. Founded in 2016, the company, formerly known as Jupiter Orphan Therapeutics, Inc., adopted its current name in August 2021 and is headquartered in Jupiter, Florida.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
Jupiter Neurosciences Announces First Patient Dosed in Phase 2a RESET Trial in Parkinson's Disease and Exploration of Strategic Options to Maximize Shareholder Value
First Patient Dosed with JOTROL ™ Marks Major Clinical Milestone for Jupiter Neurosciences' Phase 2a Study Evaluating Safety, Pharmacokinetics and Biomarkers of JOTROL ™ in Patients with Parkinson's Disease
Jupiter Neurosciences announces pricing of $2M registered direct offering
Jupiter Neurosciences announced it has entered into a securities purchase agreement for the purchase and sale of 307,692 shares of common stock in a registered direct offering. The gross proceeds of the offering are appr
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering
New York, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflamm
Jupiter Neurosciences Stock Surges Friday: What's Driving the Action?
Shares of Jupiter Neurosciences Inc. (NASDAQ:JUNS) are surging Friday morning as related biotechnology partner PharmAla Biotech Holdings Inc. announced a series of corporate updates, including a newly granted U.S. patent
Jupiter Neurosciences, Inc. Announces Reverse Stock Split
Jupiter's common stock is expected to begin trading on a post-split adjusted basis on August 7, 2026